Pharmaceutical Equipment Maker Truton Technology Ranks Top 10 in China's Most Profitable Pharma Enterprises List

　　【Pharmaceutical Station Industry Trends] Recently, "Internet Weekly" & eNet Research Institute announced a list of domestic pharmaceutical companies ranked by their "Internet+" initiatives. The list includes the top 50 pharmaceutical companies in terms of sales under the new model of "Internet+ Medicine."
 

Yunnan Baiyao Group Co., Ltd., Dalong Pharmacy of Guangdong Xueyu Tibetan Medicine Chainstore Co., Ltd., Jiangxi Jiangzhong Pharmaceutical (Group) Co., Ltd., and China Beijing Tongrentang (Group) Co., Ltd. have made it onto the list. Among them, Truking Technology Limited, a company in the pharmaceutical equipment sector, is also included. Below, we present introductions to the top 10 companies on the list.
 

　　Yunnan Baiyao Group Co., Ltd. Ranking: 1
 

The path for Yunnan Baiyao’s derivative products is endless. Much like the launch of its toothpaste in the daily necessities sector, the brand’s expansion extends beyond the pharmaceutical industry into health supplements, consumer goods, and cosmetics, representing a combination of horizontal and vertical growth. Wang Minghui, Chairman of the Board, stated, “We have an unshirkable responsibility and obligation to ensure that the esteemed Yunnan Baiyao brand maintains its strong vitality and vigor even after a century. It is precisely this sense of responsibility and mission, coupled with the pressure for survival, that serves as the inexhaustible driving force behind our innovation and transformation.”
 

　　Guangdong Xueyu Tibetan Medicine Chainstore Co., Ltd. Dalong Pharmacy Ranking: 2
 

Guangdong Xueyu Tibetan Medicine Chainstore Co., Ltd. Dalong Pharmacy mainly deals in proprietary Chinese medicines, Tibetan medicines, medicinal herbs, and local specialties, while also engaging in the trade of Tibetan handicrafts and other goods. Since its establishment, Guangdong Xueyu Tibetan Medicine Chainstore Co., Ltd. has further promoted and developed Tibetan medicine and pharmacology, achieving great success in both market presence and reputation.
 

　　Jiangxi Jiangzhong Pharmaceutical (Group) Co., Ltd. Rank: 3
 

Although Jiangzhong Pharmaceutical ranked high on this list, industry analysts note that its performance growth remains constrained by selling expenses, which is not unrelated to poor management of its core business. Notably, seemingly in response to pressure from the underperformance of its main business in the market, Jiangzhong Pharmaceutical has increased its R&D investment over the past two years. According to financial reports, Jiangzhong Pharmaceutical’s R&D expenses in 2018 amounted to RMB 29.62 million, a year-on-year increase of 30%, while R&D investment in the first quarter of 2019 surged by 158% year on year.
 

　　Beijing Tongrentang (Group) Co., Ltd. Rank: 4
 

Tongrentang achieved a revenue of RMB 14.209 billion in 2018, a year-on-year increase of 6.23%; the net profit attributable to shareholders of the listed company was RMB 1.134 billion, a year-on-year increase of 11.49%. In 2018, Tongrentang’s R&D expenses amounted to RMB 92.9115 million, representing a year-on-year increase of 1.46%. Tongrentang’s research and development department has continuously invested scientific research resources in new product development, standardization construction, common technologies, and production process improvement.
 

　　Tasly Holding Group Co., Ltd. Ranking: 5
 

Tasly initially focused primarily on the pharmaceutical manufacturing industry. Two years after its listing on the capital market, the company began to engage in the pharmaceutical distribution sector, with this segment experiencing increasing growth and accounting for a larger proportion of its business. Since its initial public offering, Tasly’s operating revenue has continued to rise, growing from an initial RMB 930 million to a revenue scale of RMB 16 billion.
 

　　CR SANJIU: 6
 

CR stated that its products boast extensive coverage and a diverse product portfolio. The self-diagnosis and treatment business covers nearly 10 categories, including colds, dermatology, gastrointestinal disorders, cough suppression, orthopedics, and pediatrics. The prescription drug business spans therapeutic areas such as oncology, cardiovascular and cerebrovascular diseases, the digestive system, orthopedics, and pediatrics. In 2018, the company had 22 product varieties with annual sales exceeding RMB 100 million each.
 

　　Lunan Pharmaceutical Group Corporation Rank: 7
 

As early as 2000, Lunan Pharmaceutical established its International Business Department to oversee the expansion of overseas markets. To date, Lunan Pharmaceutical’s products have been exported to 68 countries and regions, with sales exceeding US$100 million. Currently, the company’s export portfolio is primarily composed of active pharmaceutical ingredients (APIs).
 

　　WuXI AppTec: 8
 

Net Profit Surges by Over 70%: WuXi AppTec’s 2018 Semi-Annual Report Remains ImpressiveThe robust performance growth was primarily driven by two key factors, internal and external. The favorable external market environment fueled the rapid rise of the CRO (Contract Research Organization) industry, while WuXi AppTec’s internal corporate advantages solidified its position as the industry leader.
 

　　WOLWOPHARMA Ranking: 9
 

WOLWOPHARMA is a company capable of providing sublingual allergen immunotherapy drugs. The company continuously develops various allergen immunotherapeutic agents and diagnostic preparations, having achieved a series of core technologies in the field of allergen products. Its series of allergen immunotherapy products also fill the domestic market gap for sublingual allergen immunotherapy drugs and allergen skin prick test diagnostic reagents.
 

　　Truking Technology Limited Rank: 10
 

In recent years, TRUKING has increased its R&D investment, expanded its product portfolio, and developed comprehensive solutions, leading to an increase in market share and an overall upward trend in sales revenue. In particular, following the acquisition of Romaco, the advancement of corporate integration and the complementary synergy between products and markets have further improved sales growth expectations.